Lisata TherapeuticsLSTA +0.78%19 PS Ratio is 171.05 as of Jul. 09, 2026, which is 10204% above its 10-year median of 1.66. GuruFocus rates LSTA with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Lisata Therapeutics ranks worse than 88.37% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lisata Therapeutics's share price is $3.25.
Lisata Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Lisata Therapeutics's PS Ratio for today is 171.05.
The historical rank and industry rank for Lisata Therapeutics's PS Ratio or its related term are showing as below:
LSTA'
s PS Ratio Range Over the Past 10 Years
Min: 0.1 Med: 1.66 Max: 264.74
Current: 170.27
During the past 13 years, Lisata Therapeutics's highest PS Ratio was 264.74. The lowest was 0.10. And the median was 1.66.
LSTA's PS Ratio is ranked worse than 88.37% of 929
companies
in the Biotechnology industry
Industry Median: 9.66
vs LSTA: 170.27
During the past 13 years, Lisata Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 203.40% per year. The lowest was -62.60% per year. And the median was -21.50% per year.
Back to Basics: PS Ratio
Lisata Therapeutics (NAS:LSTA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lisata Therapeutics PS Ratio Related Terms
Lisata Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Lisata Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lisata Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lisata Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lisata Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lisata Therapeutics's Share Price of today is $3.25. Lisata Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lisata Therapeutics (LSTA) has a PS Ratio of 171.05 as of Jul. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lisata Therapeutics and its competitors. This is 10204% above median its historical median of 1.66. Over the past decade, Lisata Therapeutics' PS Ratio has ranged from 0.10 to 264.74. According to the industry distribution chart, Lisata Therapeutics ranks #821 out of 929 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Lisata Therapeutics' PS Ratio too high?
Lisata Therapeutics' current PS Ratio of 171.05 is 10204% above median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 264.74. The Biotechnology industry median PS Ratio is 9.66. Lisata Therapeutics' value of 171.05 is 1670.7% above this industry median. Based on the distribution chart, Lisata Therapeutics ranks #821 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lisata Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' PS Ratio compare to SGMO and NNVC?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #821 out of 929 companies for PS Ratio. This places Lisata Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.66. Lisata Therapeutics' value of 171.05 is 1670.7% above this benchmark. Historically, Lisata Therapeutics' own PS Ratio has ranged from 0.10 to 264.74 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 9.66, Lisata Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lisata Therapeutics's current PS Ratio of 171.05 is 1670.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lisata Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current PS Ratio is 171.05, which is 10204% above median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (LSTA) has a current PS Ratio of 171.05. The current PS Ratio is 171.05, which is 10204% above median its 10-year median of 1.66 and 1670.7% above the Biotechnology industry median of 9.66. Lisata Therapeutics' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current PS Ratio is 171.05 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
19GF Score
Get the complete analysis for LSTA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSTA has been successfully added to your 
